# WFA+M2BP in Evaluation of Portal Hypertension and Clinical Outcome in Patients With Liver Cirrhosis

> **NCT03195634** · — · UNKNOWN · sponsor: **Shanghai Changzheng Hospital** · enrollment: 80 (estimated)

## Conditions studied

- Portal Hypertension
- Cirrhosis

## Interventions

- **DRUG:** Carvedilol

## Key facts

- **NCT ID:** NCT03195634
- **Lead sponsor:** Shanghai Changzheng Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-06
- **Primary completion:** 2018-03
- **Final completion:** 2018-12
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2017-06-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03195634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03195634, "WFA+M2BP in Evaluation of Portal Hypertension and Clinical Outcome in Patients With Liver Cirrhosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03195634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*